Research on Alzheimer's disease and neurodegenerative diseases is steadily progressing. In this section you will find various news items that make up the current news in this field, in Switzerland and around the world.
Detailed results from the phase 3 clinical trial of lecanemab have been confirmed: although it does not stop the disease, the drug slows its progression. The Food and Drug Administration (FDA) has accepted the drug for marketing, following an accelerated application
The results of a global phase 3 clinical trial of lecanemab, a new treatment for Alzheimer's disease, have been published in a press release.
